Skip to content
2000
image of Efficacy of Sodium Valproate in Behavioral and Psychological Symptoms of Dementia: A Retrospective Observational Study from PUMCH Dementia Cohort

Abstract

Introduction

Behavioral and Psychological Symptoms of Dementia (BPSD) pose significant challenges for individuals with dementia and their caregivers. Agitation symptoms, in particular, present a complex management dilemma as there is a lack of consensus regarding pharmacotherapy, specifically with respect to the controversial use of valproate formulations. This study aims to assess the effectiveness of valproate treatment in addressing BPSD, with a specific focus on managing agitation symptoms in individuals with dementia.

Methods

A retrospective analysis was conducted at Peking Union Medical College Hospital (PUMCH) on patients diagnosed with BPSD who received valproate formulations between 2013 and 2023. Patients were classified into 'effective,' 'ineffective,' and 'unknown' groups based on their response to valproate treatment, and the distribution of BPSD symptoms between the effective and ineffective groups was compared.

Results

Among the 116 patients studied, 62.1% exhibited effective responses, 12.1% showed ineffectiveness, and 25.9% had uncertain outcomes with valproate therapy. While the effective group displayed a higher prevalence of agitation symptoms and other behaviors like wandering, restricted and repetitive behaviors, and sleep disturbances compared to the ineffective group, these differences did not reach statistical significance ( = 0.156, 1.000, 0.899, 0.283). Patients in the ineffective group were more likely to experience aggression with comorbid psychotic symptoms compared to those in the effective group ( = 0.023).

Discussion

Valproate may benefit agitation-predominant BPSD without psychosis. Discrepancies in prior findings may stem from differing dosing strategies. Its limited efficacy in psychosis-related aggression underscores the need for careful clinical evaluation.

Conclusion

The findings suggest that tailored valproate treatment at low doses may be beneficial in managing agitation without psychosis in Asian BPSD patients. Further validation through randomized controlled trials is essential to substantiate these observations.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/car/10.2174/0115672050383192250610115920
2025-06-16
2025-09-08

  • From This Site

    /content/journals/car/10.2174/0115672050383192250610115920
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Watt J.A. Porter J. Tavilsup P. Chowdhury M. Hatch S. Ismail Z. Kumar S. Kirkham J. Goodarzi Z. Seitz D. Guideline recommendations on behavioral and psychological symptoms of dementia: A systematic review. J. Am. Med. Dir. Assoc. 2024 25 5 837 846.e21 10.1016/j.jamda.2024.03.007 38640961
    [Google Scholar]
  2. Finkel S.I. Miller S. Silva J.C. Cohen G. Sartorius N. Behavioral and psychological signs and symptoms of dementia: A consensus statement on current knowledge and implications for research and treatment. Int. Psychogeriatr. 1997 8 Suppl. 3 497 500 10.1017/S1041610297003943 9154615
    [Google Scholar]
  3. Baillon S.F. Narayana U. Luxenberg J.S. Clifton A.V. Valproate preparations for agitation in dementia. Cochrane Database Syst. Rev. 2018 10 10 CD003945 10.1002/14651858.CD003945.pub4 30293233
    [Google Scholar]
  4. Sano M. Cummings J. Auer S. Bergh S. Fischer C.E. Gerritsen D. Agitation in cognitive disorders: Progress in the International Psychogeriatric Association consensus clinical and research definition. Int. Psychogeriatr. 2023 36 4 238 250 10.1017/S1041610222001041 36880250
    [Google Scholar]
  5. Cummings J. Sano M. Auer S. Bergh S. Fischer C.E. Gerritsen D. Reduction and prevention of agitation in persons with neurocognitive disorders: An international psychogeriatric association consensus algorithm. Int. Psychogeriatr. 2023 36 4 251 262 10.1017/S104161022200103X 36876335
    [Google Scholar]
  6. Duff, C. Dementia: Assessment, management and support for people living with dementia and their carers. 2018 Available from: https://www.nice.org.uk/guidance/ng97
  7. Diagnostic and statistical manual of mental disorders (DSM-5-TR). 2013 Available from: https://www.psychiatry.org/psychiatrists/practice/dsm
  8. Yu E. Chinese guideline of the prevention and treatment of elderly dementia. Beijing People's Medical Publishing House 2021 15 235
    [Google Scholar]
  9. Tariot P.N. Schneider L.S. Cummings J. Thomas R.G. Raman R. Jakimovich L.J. Loy R. Bartocci B. Fleisher A. Ismail M.S. Porsteinsson A. Weiner M. Jack C.R. Jr Thal L. Aisen P.S. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease. Arch. Gen. Psychiatry 2011 68 8 853 861 10.1001/archgenpsychiatry.2011.72 21810649
    [Google Scholar]
  10. Gilley D.W. Wilson R.S. Beckett L.A. Evans D.A. Psychotic symptoms and physically aggressive behavior in Alzheimer’s disease. J. Am. Geriatr. Soc. 1997 45 9 1074 1079 10.1111/j.1532‑5415.1997.tb05969.x 9288014
    [Google Scholar]
  11. Aarsland D. Cummings J.L. Yenner G. Miller B. Relationship of aggressive behavior to other neuropsychiatric symptoms in patients with Alzheimer’s disease. Am. J. Psychiatry 1996 153 2 243 247 10.1176/ajp.153.2.243 8561206
    [Google Scholar]
  12. Porsteinsson A.P. Tariot P.N. Erb R. Cox C. Smith E. Jakimovich L. Noviasky J. Kowalski N. Holt C.J. Irvine C. Placebo-controlled study of divalproex sodium for agitation in dementia. Am. J. Geriatr. Psychiatry 2001 9 1 58 66 10.1097/00019442‑200102000‑00009 11156753
    [Google Scholar]
  13. Herrmann N. Lanctôt K.L. Rothenburg L.S. Eryavec G. A placebo-controlled trial of valproate for agitation and aggression in Alzheimer’s disease. Dement. Geriatr. Cogn. Disord. 2007 23 2 116 119 10.1159/000097757 17148938
    [Google Scholar]
  14. Tariot P.N. Raman R. Jakimovich L. Schneider L. Porsteinsson A. Thomas R. Mintzer J. Brenner R. Schafer K. Thal L. Divalproex sodium in nursing home residents with possible or probable Alzheimer Disease complicated by agitation: A randomized, controlled trial. Am. J. Geriatr. Psychiatry 2005 13 11 942 949 10.1176/appi.ajgp.13.11.942 16286437
    [Google Scholar]
  15. Sival R.C. Judith Haffmans P.M. Jansen P.A.F. Duursma S.A. Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia—a randomized placebo controlled clinical trial. Int. J. Geriatr. Psychiatry 2002 17 6 579 585 10.1002/gps.653 12112183
    [Google Scholar]
  16. Tariot P.N. Schneider L.S. Mintzer J.E. Cutler A.J. Cunningham M.R. Thomas J.W. Sommerville K.W. Safety and tolerability of divalproex sodium in the treatment of signs and symptoms of mania in elderly patients with dementia: Results of a double-blind, placebo-controlled trial. Curr. Ther. Res. Clin. Exp. 2001 62 1 51 67 10.1016/S0011‑393X(01)80042‑4
    [Google Scholar]
  17. Lindley R.I. Do valproate preparations improve agitation in dementia? A cochrane review summary with commentary. Australas. J. Ageing 2021 40 3 336 338 10.1111/ajag.12984 34390114
    [Google Scholar]
  18. Liu J. Wang L. Efficacy and safety of valproic acid in dementia: A systematic review with meta-analysis. Arch. Gerontol. Geriatr. 2020 89 104091 10.1016/j.archger.2020.104091 32413690
    [Google Scholar]
  19. Dolder C. Mckinsey J. Low-dose divalproex in agitated patients with Alzheimer’s disease. J. Psychiatr. Pract. 2010 16 1 63 67 10.1097/01.pra.0000367781.26507.86 20098234
    [Google Scholar]
  20. Forester B. Vanelli M. Hyde J. Perez R. Ahokpossi C. Sribney W. Adkison L. Report on an open-label prospective study of divalproex sodium for the behavioral and psychological symptoms of dementia as monotherapy and in combination with second-generation antipsychotic medication. Am. J. Geriatr. Pharmacother. 2007 5 3 209 217 10.1016/j.amjopharm.2007.09.001 17996660
    [Google Scholar]
  21. Sival R.C. Duivenvoorden H.J. Jansen P.A.F. Haffmans P.M.J. Duursma S.A. Eikelenboom P. Sodium valproate in aggressive behaviour in dementia: A twelve-week open label follow-up study. Int. J. Geriatr. Psychiatry 2004 19 4 305 312 10.1002/gps.1034 15065222
    [Google Scholar]
  22. Porsteinsson A.P. Tariot P.N. Jakimovich L.J. Kowalski N. Holt C. Erb R. Cox C. Valproate therapy for agitation in dementia: Open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry 2003 11 4 434 440 10.1097/00019442‑200307000‑00006 12837672
    [Google Scholar]
  23. Herrmann N. Valproic acid treatment of agitation in dementia. Can. J. Psychiatry 1998 43 1 69 72 10.1177/070674379804300108 9494750
    [Google Scholar]
  24. Dolder C.R. Nealy K.L. McKinsey J. Valproic acid in dementia: Does an optimal dose exist? J. Pharm. Pract. 2012 25 2 142 150 10.1177/0897190011424802 22095580
    [Google Scholar]
  25. Frederiksen K.S. Cooper C. Frisoni G.B. Frölich L. Georges J. Kramberger M.G. Nilsson C. Passmore P. Mantoan Ritter L. Religa D. Schmidt R. Stefanova E. Verdelho A. Vandenbulcke M. Winblad B. Waldemar G. A European Academy of Neurology guideline on medical management issues in dementia. Eur. J. Neurol. 2020 27 10 1805 1820 10.1111/ene.14412 32713125
    [Google Scholar]
  26. Shaji K.S. Sivakumar P.T. Rao G.P. Paul N. Clinical practice guidelines for management of dementia. Indian J. Psychiatry 2018 60 7 Suppl. 3 312 10.4103/0019‑5545.224472 29535467
    [Google Scholar]
  27. Reus V.I. Fochtmann L.J. Eyler A.E. Hilty D.M. Horvitz-Lennon M. Jibson M.D. Lopez O.L. Mahoney J. Pasic J. Tan Z.S. Wills C.D. Rhoads R. Yager J. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Focus Am. Psychiatr. Publ. 2017 15 1 81 84 10.1176/appi.focus.15107 31997967
    [Google Scholar]
  28. Masopust J. Protopopová D. Vališ M. Pavelek Z. Klímová B. Treatment of behavioral and psychological symptoms of dementias with psychopharmaceuticals: A review. Neuropsychiatr. Dis. Treat. 2018 14 1211 1220 10.2147/NDT.S163842 29785112
    [Google Scholar]
  29. Zhang C. Sun L. Sun H. Effects of magnesium valproate adjuvant therapy on patients with dementia: A systematic review and meta-analysis. Medicine 2022 101 31 e29642 10.1097/MD.0000000000029642 35945786
    [Google Scholar]
  30. Bjerre L.M. Farrell B. Hogel M. Graham L. Lemay G. McCarthy L. Raman-Wilms L. Rojas-Fernandez C. Sinha S. Thompson W. Welch V. Wiens A. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: Evidence-based clinical practice guideline. Can. Fam. Physician 2018 64 1 17 27 29358245
    [Google Scholar]
  31. Reus V.I. Fochtmann L.J. Eyler A.E. Hilty D.M. Horvitz-Lennon M. Jibson M.D. Lopez O.L. Mahoney J. Pasic J. Tan Z.S. Wills C.D. Rhoads R. Yager J. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am. J. Psychiatry 2016 173 5 543 546 10.1176/appi.ajp.2015.173501 27133416
    [Google Scholar]
  32. Sorbi S. Hort J. Erkinjuntti T. Fladby T. Gainotti G. Gurvit H. Nacmias B. Pasquier F. Popescu B.O. Rektorova I. Religa D. Rusina R. Rossor M. Schmidt R. Stefanova E. Warren J.D. Scheltens P. EFNS-ENS Guidelines on the diagnosis and management of disorders associated with dementia. Eur. J. Neurol. 2012 19 9 1159 1179 10.1111/j.1468‑1331.2012.03784.x 22891773
    [Google Scholar]
  33. McShane R. Westby M.J. Roberts E. Minakaran N. Schneider L. Farrimond L.E. Maayan N. Ware J. Debarros J. Memantine for dementia. Cochrane Database Syst. Rev. 2019 3 3 CD003154 10.1002/14651858.CD003154.pub6 30891742
    [Google Scholar]
  34. Chen R. Chan P.T. Chu H. Lin Y.C. Chang P.C. Chen C.Y. Chou K.R. Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS One 2017 12 8 e0183586 10.1371/journal.pone.0183586 28827830
    [Google Scholar]
/content/journals/car/10.2174/0115672050383192250610115920
Loading
Efficacy of Sodium Valproate in Behavioral and Psychological Symptoms of Dementia: A Retrospective Observational Study from PUMCH Dementia Cohort
Bentham Science Publishers ; https://doi.org/10.2174/0115672050383192250610115920
/content/journals/car/10.2174/0115672050383192250610115920
/content/journals/car/10.2174/0115672050383192250610115920
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: valproic acid ; aberrant motor behavior in dementia ; Dementia ; behavioral and psychological symptoms ; aggression ; dementia agitation ; psychomotor agitation

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test